Across the global pharmaceutical and biotechnology industry, structural changes are leading
companies to rethink their business models. This has led to a period of experimentation and
accelerated evolution of business models.
This document is a presentation by Chris Bogan, Best Practices, LLC chief executive, that reviews nine approaches - from benchmarking to lifecycle studies - to understand the future and to navigate through the turbulence of current change. The presentation contains performance benchmarks from Best Practices, LLC research that highlight factors that can inform executives who are facing a changing marketplace landscape.
SAMPLE KEY METRICS
What are the planned changes to your sales model?
What changes do you expect to see in your sales force size?
How will the operating budget for your CI program change in the next year?
Estimate the mix of your published papers for Phase III to Launch period.